NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
tumors lacking BRAF and NRAS mutations, suggesting that this tumor-informed approach may be informative in a wider range of patients. The study provides a foundation for future research and integration into routine clinical care, aiming to improve patient outcomes. The findings have also led to the development of the CLEAR-Me trial, an interception study to detect and clear MRD in patients with high-risk melanoma. The study highlights the value of ctDNA in addressing the need for dependable biomarkers to define recurrence risk and identify melanoma patients who would benefit most from adjuvant treatment. The study found that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence. NeoGenomics is a premier cancer diagnostics company specializing in cancer genetics testing and information services, offering one of the most comprehensive oncology-focused testing menus across th
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics [Yahoo! Finance]Yahoo! Finance
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target raised by analysts at Bank of America Co. from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk MelanomaBusiness Wire
- NeoGenomics, Inc. (NASDAQ: NEO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 11/5/24 - Beat
NEO
Sec Filings
- 12/10/24 - Form 4
- 12/4/24 - Form 4/A
- 12/4/24 - Form 4/A
- NEO's page on the SEC website